Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

GEHC US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

GE HealthCare Technologies Inc.(GEHC US)

$82.60-1.051.26%Ext:$82.93+0.330.40%(After Hours · 23:03:39 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

GEHC US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

GE HealthCare Technologies Inc.(GEHC US)

$82.60-1.051.26%Ext:$82.93+0.330.40%(After Hours · 23:03:39 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

GE HealthCare Technologies Inc. — Company Profile

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Peter J. Arduini
Headquarters
Chicago, IL, US
IPO Date
Dec 15, 2022
Employees
54,000
Website
www.gehealthcare.com

Key Metrics

Price
$64.16

GE HealthCare Technologies Inc. — Company Profile

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Peter J. Arduini
Headquarters
Chicago, IL, US
IPO Date
Dec 15, 2022
Employees
54,000
Website
www.gehealthcare.com

Key Metrics

Price
$64.16
Market Cap
$28.98B
Revenue (TTM)
$5.13B
Net Income (TTM)
$389.00M
EPS (TTM)
0.85
P/E (TTM)
19.26
P/B (TTM)
2.72
Dividend Yield
19.90%
ROE (TTM)
3.65%
ROA (TTM)
1.05%
Operating Margin
10.04%
Beta
1.05

Dividends

Last Dividend
$0.04
Last Yield
0.20%

Summary

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Website
www.gehealthcare.com
Location
Chicago, IL, US
Phone833 735 1139
Employees54,000
CEOPeter J. Arduini
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateDec 15, 2022

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(440)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers5 Nov
  • Form 144SACCARO JAMES4 Nov
  • 10-QQ3ended 30 Sept 202628 Oct
  • 8-KResults of Operations and Financial Condition28 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers22 Sep
  • Form 4Grogan William K16 Sep
  • Form 3Grogan William K16 Sep
  • Form 4Rackliffe Philip4 Sep
  • Form 4O'Neill Kevin Michael4 Sep
  • Form 4Newcomb George A.4 Sep
  • Form 4Kass-Hout Taha4 Sep
  • Form 4Jimenez Frank R4 Sep
  • Form 4Holton Adam Y4 Sep
  • Form 4Estrampes Catherine4 Sep
  • Form 4Arduini Peter J4 Sep
  • Form 4Rackliffe Philip3 Sep
  • Form 4Kass-Hout Taha3 Sep
  • Form 4Jimenez Frank R3 Sep
  • Form 4Holton Adam Y3 Sep
  • Form 4Bankes Jeannette3 Sep

News

  • GE HealthCare: 3 Key Takeaways for Long-Term Investors11 Nov
  • GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS10 Nov
  • GE HealthCare Technologies (GEHC) is a Top-Ranked Value Stock: Should You Buy?10 Nov
  • GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience10 Nov
  • GE HealthCare Unveils Allia Celeo to Advance Interventional Imaging5 Nov
  • GEHC Q3 Earnings Call Highlights Raised Outlook and Margin Risks4 Nov
  • GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments3 Nov
  • GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments3 Nov
  • GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging1 Nov
  • GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging1 Nov
  • GEHC vs. HAE: Which Stock Is the Better Value Option?29 Oct
  • GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling29 Oct
  • GE HealthCare Technologies Q3 Earnings Call Highlights28 Oct
  • GE HealthCare Lifts Forecasts on Healthy Hospital Spending28 Oct
  • GE HealthCare Technologies Inc. (GEHC) Q3 2026 Earnings Call Transcript28 Oct
  • GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View Raised28 Oct
  • Compared to Estimates, GE HealthCare (GEHC) Q3 Earnings: A Look at Key Metrics28 Oct
  • GE HealthCare Technologies (GEHC) Q3 Earnings and Revenues Beat Estimates28 Oct
  • GE HealthCare reports third quarter 2026 financial results28 Oct
  • GEHC Ahead of Q3 Earnings: Can Strong Demand Offset Macro Headwinds?27 Oct

Mentions in Filings

  • … reement with the Company to assist with the transition of his duties and responsibilities to Ms. Bankes. Ms. Bankes, age 56, has served as the President and Chief Executive Officer, Patient Care Solutions of <strong>GE Healthcare Technologies Inc.</strong> (Nasdaq: GEHC) since May 2025. Her last day at GE Healthcare will be November 15, 2026. Previously, Ms. Bankes served as President, Global Franchises at Alcon Inc. (NYSE: ALC), a global manufacturer of vision …
    TANDEM DIABETES CARE INCGE HealthCare Technologies Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov
  • … leveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery. During the last five years, he previously served as a director of General Electric Company (General Electric) and <strong>GE HealthCare Technologies Inc.</strong> (GE HealthCare). Qualifications: As the Chief Executive Officer and President of Cleveland Clinic, Dr. Mihaljevic brings to the Board extensive experience leading a large, complex global healthcare organizatio …
    ORACLE CORPGE HealthCare Technologies Inc.·DEF 14A - Definitive proxy statement·Q2 27·25 Sep
  • … Evercore reviewed and compared certain financial information of Varex to corresponding financial multiples and ratios for the following selected publicly traded companies: • Siemens Healthineers AG ​ • <strong>GE HealthCare Technologies Inc.</strong> ​ • Teledyne Technologies Incorporated ​ • Koninklijke Philips N.V. ​ • OSI Systems, Inc. ​ • Integra LifeSciences Holdings Corporation ​ • Enovis Corporation ​ • Elekta AB ​ • Omnicell, I …
    Varex Imaging CorpGE HealthCare Technologies Inc.·DEFM14A - Definitive proxy statement (merger)·Q4 26·21 Sep
  • … Evercore reviewed and compared certain financial information of Varex to corresponding financial multiples and ratios for the following selected publicly traded companies: • Siemens Healthineers AG ​ • <strong>GE HealthCare Technologies Inc.</strong> ​ • Teledyne Technologies Incorporated ​ • Koninklijke Philips N.V. ​ • OSI Systems, Inc. ​ • Integra LifeSciences Holdings Corporation ​ • Enovis Corporation ​ • Elekta AB ​ • Omnicell, I …
    Varex Imaging CorpGE HealthCare Technologies Inc.·PREM14A - Preliminary proxy statement (merger)·Q4 26·8 Sep
  • … erved as Chief Executive Officer of several privately-held companies, including Altiras Holdings, Chasm Industries and Market2Market. Earlier in his career, he served in several senior management positions at <strong>GE HealthCare Technologies Inc.</strong>, playing a key role in developing and leading various service businesses. Mr. Marshall earned a Bachelor of Science degree in Electrical Engineering from The Ohio State University and completed a postgraduate …
    Bravo Multinational Inc.GE HealthCare Technologies Inc.·10-Q - QTR. REPORT - JUNE 30, 2026 Q2·Q2 26·19 Aug
  • … | | | | AMGN | Amgen Inc. | | 3.38% | | 13 | | 466.01 | | 6,058 | | CI | The Cigna Group | | 3.33% | | 20 | | 298.23 | | 5,965 | | CVS | CVS Health Corporation | | 3.33% | | 66 | | 90.25 | | 5,956 | | GEHC | <strong>GE HealthCare Technologies Inc.</strong> | | 3.34% | | 78 | | 76.57 | | 5,972 | | JNJ | Johnson & Johnson | | 3.36% | | 22 | | 273.20 | | 6,010 | | MRK | Merck & Co., Inc. | | 3.34% | | 40 | | 149.52 | | 5,981 | | Industrials (23.27%): | | | | | | | …
    FT 13311GE HealthCare Technologies Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·2 Nov

Key Stats

Trading

Px/Chg 1D$64.16 / -0.20%
Avg Volume4.55M
Beta1.05
Mkt Cap28.98B
FD Mkt Cap32.13B

Float

Shrs Out/Float451.69M / 450.34M
Short Float0.03%
Days to Cover2.53
Stock Repurchased$100.00M

Current Valuation

EV37.50B
EV/EBITDA11.04
EV/Sales1.88
P/B2.72
P/S1.45
FCF Yield0.39%
ROE3.65%
ROA1.05%
Current Ratio1.17

Dividend

Cash$0.04
Yield19.90%
Yield (TTM)19.90%

Estimates

P/E19.26
Est P/E0.00
Est EPS1.04
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings61.3320.8025.8115.58169.9674.50
Price / Sales3.632.172.071.586.695.65
Price / Book Value3.874.265.673.683.012.72
Price / Free Cash Flow71.7222.1023.6120.0334.10258.75
ENTERPRISE VALUE METRICS
Enterprise Value41,501.047,275.248,003.737,741.036,982.737,502.2
Enterprise Value / Sales4.432.582.461.927.917.31
Enterprise Value / EBITDA26.2614.9413.6610.2942.7549.67
Enterprise Value / EBIT45.2818.6716.5412.23116.6662.30

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%17,585.018,341.019,552.019,672.020,625.0
Gross Income3.5%7,174.07,179.07,922.08,205.08,247.0
EBITDA1.7%3,540.03,165.03,513.03,666.03,785.0
EBIT2.4%2,915.02,532.02,903.03,086.03,207.0
Net Income-1.9%2,247.01,916.01,568.01,993.02,084.0
EPS (Diluted)-1.8%4.904.223.024.344.55
BALANCE SHEET
Cash & ST Inv68.8%556.01,445.02,504.02,890.04,512.0
Total Assets8.8%26,308.027,539.032,454.033,089.036,906.0
Total Liabilities29.3%9,412.017,947.025,144.024,436.026,307.0
Total Shareholder Equity-11.2%16,655.09,357.07,133.08,447.010,379.0
CASH FLOW
Net Operating Cash Flow5.5%1,607.02,113.02,101.01,951.01,988.0
Cap Ex18.1%-248.0-310.0-387.0-401.0-482.0
Free Cash Flow2.6%1,359.01,803.01,714.01,550.01,506.0

Enterprise Value Bridge

Millions USD11 Nov '26
Price (As of 11 Nov '26)82.58
Basic Shares451.69
Market Cap37,300.3
Diluted Shares453.00
Fully Diluted Shares Outstanding453.00
Fully Diluted Market Cap37,408.7
+Consolidated Debt10,407.0
−In-the-Money Convertible Debt—
+Capital Leases434.0
+Operating Leases—
−Cash & Equivalents-2,854.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest251.0
+Pension Liabilities—
Enterprise Value45,104.3

Segment data

Revenue

by Products and services

  • Imaging Segment61%
  • Pcs Segment20%
  • Pdx Segment19%

Revenue

by Geography

  • Other Countries46%
  • United States44%
  • China10%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

Market Cap
$28.98B
Revenue (TTM)
$5.13B
Net Income (TTM)
$389.00M
EPS (TTM)
0.85
P/E (TTM)
19.26
P/B (TTM)
2.72
Dividend Yield
19.90%
ROE (TTM)
3.65%
ROA (TTM)
1.05%
Operating Margin
10.04%
Beta
1.05

Dividends

Last Dividend
$0.04
Last Yield
0.20%

Summary

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Website
www.gehealthcare.com
Location
Chicago, IL, US
Phone833 735 1139
Employees54,000
CEOPeter J. Arduini
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateDec 15, 2022

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(440)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers5 Nov
  • Form 144SACCARO JAMES4 Nov
  • 10-QQ3ended 30 Sept 202628 Oct
  • 8-KResults of Operations and Financial Condition28 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers22 Sep
  • Form 4Grogan William K16 Sep
  • Form 3Grogan William K16 Sep
  • Form 4Rackliffe Philip4 Sep
  • Form 4O'Neill Kevin Michael4 Sep
  • Form 4Newcomb George A.4 Sep
  • Form 4Kass-Hout Taha4 Sep
  • Form 4Jimenez Frank R4 Sep
  • Form 4Holton Adam Y4 Sep
  • Form 4Estrampes Catherine4 Sep
  • Form 4Arduini Peter J4 Sep
  • Form 4Rackliffe Philip3 Sep
  • Form 4Kass-Hout Taha3 Sep
  • Form 4Jimenez Frank R3 Sep
  • Form 4Holton Adam Y3 Sep
  • Form 4Bankes Jeannette3 Sep

News

  • GE HealthCare: 3 Key Takeaways for Long-Term Investors11 Nov
  • GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS10 Nov
  • GE HealthCare Technologies (GEHC) is a Top-Ranked Value Stock: Should You Buy?10 Nov
  • GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience10 Nov
  • GE HealthCare Unveils Allia Celeo to Advance Interventional Imaging5 Nov
  • GEHC Q3 Earnings Call Highlights Raised Outlook and Margin Risks4 Nov
  • GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments3 Nov
  • GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments3 Nov
  • GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging1 Nov
  • GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging1 Nov
  • GEHC vs. HAE: Which Stock Is the Better Value Option?29 Oct
  • GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling29 Oct
  • GE HealthCare Technologies Q3 Earnings Call Highlights28 Oct
  • GE HealthCare Lifts Forecasts on Healthy Hospital Spending28 Oct
  • GE HealthCare Technologies Inc. (GEHC) Q3 2026 Earnings Call Transcript28 Oct
  • GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View Raised28 Oct
  • Compared to Estimates, GE HealthCare (GEHC) Q3 Earnings: A Look at Key Metrics28 Oct
  • GE HealthCare Technologies (GEHC) Q3 Earnings and Revenues Beat Estimates28 Oct
  • GE HealthCare reports third quarter 2026 financial results28 Oct
  • GEHC Ahead of Q3 Earnings: Can Strong Demand Offset Macro Headwinds?27 Oct

Mentions in Filings

  • … reement with the Company to assist with the transition of his duties and responsibilities to Ms. Bankes. Ms. Bankes, age 56, has served as the President and Chief Executive Officer, Patient Care Solutions of <strong>GE Healthcare Technologies Inc.</strong> (Nasdaq: GEHC) since May 2025. Her last day at GE Healthcare will be November 15, 2026. Previously, Ms. Bankes served as President, Global Franchises at Alcon Inc. (NYSE: ALC), a global manufacturer of vision …
    TANDEM DIABETES CARE INCGE HealthCare Technologies Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov
  • … leveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery. During the last five years, he previously served as a director of General Electric Company (General Electric) and <strong>GE HealthCare Technologies Inc.</strong> (GE HealthCare). Qualifications: As the Chief Executive Officer and President of Cleveland Clinic, Dr. Mihaljevic brings to the Board extensive experience leading a large, complex global healthcare organizatio …
    ORACLE CORPGE HealthCare Technologies Inc.·DEF 14A - Definitive proxy statement·Q2 27·25 Sep
  • … Evercore reviewed and compared certain financial information of Varex to corresponding financial multiples and ratios for the following selected publicly traded companies: • Siemens Healthineers AG ​ • <strong>GE HealthCare Technologies Inc.</strong> ​ • Teledyne Technologies Incorporated ​ • Koninklijke Philips N.V. ​ • OSI Systems, Inc. ​ • Integra LifeSciences Holdings Corporation ​ • Enovis Corporation ​ • Elekta AB ​ • Omnicell, I …
    Varex Imaging CorpGE HealthCare Technologies Inc.·DEFM14A - Definitive proxy statement (merger)·Q4 26·21 Sep
  • … Evercore reviewed and compared certain financial information of Varex to corresponding financial multiples and ratios for the following selected publicly traded companies: • Siemens Healthineers AG ​ • <strong>GE HealthCare Technologies Inc.</strong> ​ • Teledyne Technologies Incorporated ​ • Koninklijke Philips N.V. ​ • OSI Systems, Inc. ​ • Integra LifeSciences Holdings Corporation ​ • Enovis Corporation ​ • Elekta AB ​ • Omnicell, I …
    Varex Imaging CorpGE HealthCare Technologies Inc.·PREM14A - Preliminary proxy statement (merger)·Q4 26·8 Sep
  • … erved as Chief Executive Officer of several privately-held companies, including Altiras Holdings, Chasm Industries and Market2Market. Earlier in his career, he served in several senior management positions at <strong>GE HealthCare Technologies Inc.</strong>, playing a key role in developing and leading various service businesses. Mr. Marshall earned a Bachelor of Science degree in Electrical Engineering from The Ohio State University and completed a postgraduate …
    Bravo Multinational Inc.GE HealthCare Technologies Inc.·10-Q - QTR. REPORT - JUNE 30, 2026 Q2·Q2 26·19 Aug
  • … | | | | AMGN | Amgen Inc. | | 3.38% | | 13 | | 466.01 | | 6,058 | | CI | The Cigna Group | | 3.33% | | 20 | | 298.23 | | 5,965 | | CVS | CVS Health Corporation | | 3.33% | | 66 | | 90.25 | | 5,956 | | GEHC | <strong>GE HealthCare Technologies Inc.</strong> | | 3.34% | | 78 | | 76.57 | | 5,972 | | JNJ | Johnson & Johnson | | 3.36% | | 22 | | 273.20 | | 6,010 | | MRK | Merck & Co., Inc. | | 3.34% | | 40 | | 149.52 | | 5,981 | | Industrials (23.27%): | | | | | | | …
    FT 13311GE HealthCare Technologies Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·2 Nov

Key Stats

Trading

Px/Chg 1D$64.16 / -0.20%
Avg Volume4.55M
Beta1.05
Mkt Cap28.98B
FD Mkt Cap32.13B

Float

Shrs Out/Float451.69M / 450.34M
Short Float0.03%
Days to Cover2.53
Stock Repurchased$100.00M

Current Valuation

EV37.50B
EV/EBITDA11.04
EV/Sales1.88
P/B2.72
P/S1.45
FCF Yield0.39%
ROE3.65%
ROA1.05%
Current Ratio1.17

Dividend

Cash$0.04
Yield19.90%
Yield (TTM)19.90%

Estimates

P/E19.26
Est P/E0.00
Est EPS1.04
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings61.3320.8025.8115.58169.9674.50
Price / Sales3.632.172.071.586.695.65
Price / Book Value3.874.265.673.683.012.72
Price / Free Cash Flow71.7222.1023.6120.0334.10258.75
ENTERPRISE VALUE METRICS
Enterprise Value41,501.047,275.248,003.737,741.036,982.737,502.2
Enterprise Value / Sales4.432.582.461.927.917.31
Enterprise Value / EBITDA26.2614.9413.6610.2942.7549.67
Enterprise Value / EBIT45.2818.6716.5412.23116.6662.30

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%17,585.018,341.019,552.019,672.020,625.0
Gross Income3.5%7,174.07,179.07,922.08,205.08,247.0
EBITDA1.7%3,540.03,165.03,513.03,666.03,785.0
EBIT2.4%2,915.02,532.02,903.03,086.03,207.0
Net Income-1.9%2,247.01,916.01,568.01,993.02,084.0
EPS (Diluted)-1.8%4.904.223.024.344.55
BALANCE SHEET
Cash & ST Inv68.8%556.01,445.02,504.02,890.04,512.0
Total Assets8.8%26,308.027,539.032,454.033,089.036,906.0
Total Liabilities29.3%9,412.017,947.025,144.024,436.026,307.0
Total Shareholder Equity-11.2%16,655.09,357.07,133.08,447.010,379.0
CASH FLOW
Net Operating Cash Flow5.5%1,607.02,113.02,101.01,951.01,988.0
Cap Ex18.1%-248.0-310.0-387.0-401.0-482.0
Free Cash Flow2.6%1,359.01,803.01,714.01,550.01,506.0

Enterprise Value Bridge

Millions USD11 Nov '26
Price (As of 11 Nov '26)82.58
Basic Shares451.69
Market Cap37,300.3
Diluted Shares453.00
Fully Diluted Shares Outstanding453.00
Fully Diluted Market Cap37,408.7
+Consolidated Debt10,407.0
−In-the-Money Convertible Debt—
+Capital Leases434.0
+Operating Leases—
−Cash & Equivalents-2,854.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest251.0
+Pension Liabilities—
Enterprise Value45,104.3

Segment data

Revenue

by Products and services

  • Imaging Segment61%
  • Pcs Segment20%
  • Pdx Segment19%

Revenue

by Geography

  • Other Countries46%
  • United States44%
  • China10%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN